Artelo Biosciences (NASDAQ:ARTL – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.10, Yahoo Finance reports.
Artelo Biosciences Price Performance
Artelo Biosciences stock traded down $0.04 during midday trading on Thursday, hitting $1.28. 1,638 shares of the stock were exchanged, compared to its average volume of 42,441. Artelo Biosciences has a 1 year low of $1.15 and a 1 year high of $2.98. The firm has a market cap of $4.12 million, a P/E ratio of -0.42 and a beta of 1.43. The company has a 50 day moving average price of $1.33 and a two-hundred day moving average price of $1.41.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Artelo Biosciences in a report on Wednesday.
About Artelo Biosciences
Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
See Also
- Five stocks we like better than Artelo Biosciences
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What is a buyback in stocks? A comprehensive guide for investors
- Jeff Brown’s Exegesis AI Stock Picks
- Roth IRA Calculator: Calculate Your Potential Returns
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.